Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects
Authors:
- 29 May 2021
- journal article
- research article
- Published by Springer Nature in Bulletin of Experimental Biology and Medicine
- Vol. 171 (1) , 109-121
Abstract
Epidermolysis bullosa is a severe hereditary disease caused by mutations in genes encoding cutaneous basement membrane proteins. These mutations lead to dermal-epidermal junction failure and, as a result, to disturbances in the morphological integrity of the skin. Clinically, it manifests in the formation of blisters on the skin or mucosa that in some cases can turn into non-healing chronic wounds, which not only impairs patient’s quality of life, but also is a live-threatening condition. Now, the main approaches in the treatment of epidermolysis bullosa are symptomatic therapy and palliative care, though they are little effective and are aimed at reducing the pain, but not to complete recovery. In light of this, the development of new treatment approaches aimed at correction of genetic defects is in progress. Various methods based on genetic engineering technologies, transplantation of autologous skin cells, progenitor skin cells, as well as hematopoietic and mesenchymal stem cells are studied. This review analyzes the pathogenetic methods developed for epidermolysis bullosa treatment based on the latest achievements of molecular genetics and cellular technologies, and discusses the prospects for the use of these technologies for the therapy of epidermolysis bullosa.Keywords
This publication has 91 references indexed in Scilit:
- Defining Keratin Protein Function in Skin Epithelia: Epidermolysis Bullosa Simplex and Its AftermathJournal of Investigative Dermatology, 2012
- Revertant mosaicism in skin: natural gene therapyTrends in Molecular Medicine, 2011
- Long-Term Type VII Collagen Restoration to Human Epidermolysis Bullosa Skin TissueHuman Gene Therapy, 2010
- A prevalent mutation with founder effect in Spanish Recessive Dystrophic Epidermolysis Bullosa familiesBMC Medical Genetics, 2010
- Bone Marrow Transplantation for Recessive Dystrophic Epidermolysis BullosaNew England Journal of Medicine, 2010
- First-in-human Mutation-targeted siRNA Phase Ib Trial of an Inherited Skin DisorderMolecular Therapy, 2010
- Epidermolysis bullosa simplex: a paradigm for disorders of tissue fragilityJournal of Clinical Investigation, 2009
- Amelioration of epidermolysis bullosa by transfer of wild-type bone marrow cellsBlood, 2009
- Epithelial Stem Cells: Turning over New LeavesCell, 2007
- Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cellsNature Medicine, 2006